Prostate Cancer Coverage from Every Angle

Role of ADT in Efficacy of Docetaxel in Metastatic Castration-Resistant Prostate Cancer

By: Susan Reckling
Posted: Tuesday, October 6, 2020

According to the findings of a multicenter randomized phase III study of the Italian Piemonte Oncology Network, the efficacy of docetaxel did not appear to be influenced by the maintenance or suspension of androgen-deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer. In fact, the continuous or intermittent schedule of treatment administration also does not appear to play a role in its efficacy. Alfredo Berruti, MD, of Azienda Ospedaliera Spedali Civili di Brescia, Italy, and colleagues presented these results as an e-poster at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 619P).

A total of 198 patients took part in this trial between 2010 and 2014. During the first randomization, approximately half of patients received docetaxel and maintenance with a luteinizing hormone-releasing hormone agonist (LHRH-A), and the others received docetaxel with a suspension of LHRH-A. During the second randomization, patients who were free of disease progression after four cycles of docetaxel received continuous (n = 35) or intermittent (n = 42) docetaxel therapy.

The investigators reported a prostate-specific antigen (PSA) response in 43.8% of those who maintained LHRH-A therapy and 38.2% of those who suspended LHRH-A. For those who maintained LHRH-A therapy, the median progression-free survival was 10.3 months, and the corresponding median overall survival was 23.3 months, compared with 10.8 months and 24.8 months for those who suspended LHRH-A therapy. The hazard ratio for both progression-free survival and overall survival was 1.02, with a P value of .9.

As for toxicity, no differences were noted between the two treatment arms. Serum testosterone levels increased above the castration range after 6 months of therapy in 22.8% of those who maintained therapy with LHRH-A, and normal testosterone levels were reached by 5.9% of those who suspended therapy with LHRH-A after 6 months of therapy.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.